QURE
$15.62
uniQure N.V.
Intraday
Recent News
Biotechs Breathe Easy As Vinay Prasad Plans His Exit. But Should They?
The FDA's embattled vaccine chief, Vinay Prasad, will exit the agency. But that doesn't mean biotech stocks should breathe easy.
Biotech Stocks Rally on Departure of Polarizing FDA Official
Biotech investors have rarely united so strongly against a Food and Drug Administration official as they did against Vinay Prasad, who led the FDA's vaccines and related biological products division and blocked several rare-disease drugs from receiving accelerated approval. Prasad’s stance had weighed heavily on the stocks of companies developing the drugs. Now those stocks are rallying after FDA Commissioner Marty Makary said Friday in an interview that Prasad will be departing at the end of April.
uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
Wall Street is turning constructive on three clinical-stage biotechs simultaneously, each sitting at the edge of a binary catalyst. The analyst calls on uniQure (NASDAQ:QURE), Syndax Pharmaceuticals (NASDAQ:SNDX), and Erasca (NASDAQ:ERAS) share a common thread: analysts see asymmetric upside in names where the market has not yet priced in the full probability of success. uniQure: ... uniQure, Syndax and Erasca Are Drawing Analyst Interest Ahead of Key Drug Catalysts
uniQure stock surges 36% on FDA official’s departure
Investing.com -- uniQure BV (NASDAQ:QURE) shares surged 36% Monday following reports that the head of the US Food and Drug Administration’s division of vaccines and gene therapies is leaving the agency, prompting multiple analyst upgrades across the biotech sector. REGENXBIO (NASDAQ:RGNX) rose 13% and Biohaven (NYSE:BHVN) gained 23%.
Shifting Narrative For uniQure (QURE) As FDA Trial Demands Reshape AMT-130 Expectations
uniQure’s modelled fair value has been reduced from about US$53.54 to about US$28.67 per share, a cut of close to 50% in the latest update. This reset aligns with Street research, where some firms have sharply reduced targets after the FDA signaled a randomized, sham controlled Phase 3 trial for AMT-130, and published views now range from single digits to US$70. As you read on, you will see what is driving this divergence in opinion and how you can track the evolving story from here. Stay...